Engineered cells expressing multiple immunomodulators and uses thereof
US10046049B2 · kind B2 · utility
3Cited by
7References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2016 |
| Grant date | Aug 14, 2018 |
| Priority date | — |
| Expiry date | Sep 26, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/206
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.